Last $8.89 USD
Change Today -0.0001 / 0.00%
Volume 717.0
AQXP On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

aquinox pharmaceuticals inc (AQXP) Snapshot

Open
$8.89
Previous Close
$8.89
Day High
$9.11
Day Low
$8.89
52 Week High
03/13/14 - $14.35
52 Week Low
04/29/14 - $8.26
Market Cap
94.9M
Average Volume 10 Days
7.4K
EPS TTM
--
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AQUINOX PHARMACEUTICALS INC (AQXP)

Related News

No related news articles were found.

aquinox pharmaceuticals inc (AQXP) Related Businessweek News

No Related Businessweek News Found

aquinox pharmaceuticals inc (AQXP) Details

Aquinox Pharmaceuticals Inc., a clinical stage pharmaceutical company, discovers and develops oral drug candidates for the treatment of inflammatory diseases and cancer. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its principal product candidate is AQX-1125, a SHIP1 activator, which is in Phase II clinical trials for chronic obstructive pulmonary disease and bladder pain syndrome/interstitial cystitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

14 Employees
Last Reported Date: 05/13/14
Founded in 2003

aquinox pharmaceuticals inc (AQXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $420.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $183.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $270.2K
Compensation as of Fiscal Year 2013.

aquinox pharmaceuticals inc (AQXP) Key Developments

Aquinox Pharmaceuticals Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 09:30 AM

Aquinox Pharmaceuticals Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, Jun-18-2014 09:30 AM. Venue: Toronto Board of Trade, 1 First Canadian Place (Corner of Bay and Adelaide), Toronto, ON M5X 1C1, Canada.

Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND

Aquinox Pharmaceuticals Inc. announced expansion of its ongoing Phase 2 clinical trials with its lead product candidate, AQX-1125. The U.S. Food and Drug Administration has accepted Aquinox's Investigational New Drug (IND) application for the Phase 2 LEADERSHIP trial, which is investigating the safety and efficacy of AQX-1125 in reducing pain and urinary symptoms in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). The LEADERSHIP trial has been enrolling patients at clinical sites across Canada and is now active at sites in the United States. In addition, Aquinox announced that it is expanding its Phase 2 FLAGSHIP trial investigating the safety and efficacy of AQX-1125 in the treatment of exacerbations of chronic obstructive pulmonary disease after having obtained regulatory clearance in Australia, where it is currently adding clinical sites. Aquinox is also seeking regulatory clearance to add clinical sites in New Zealand. FLAGSHIP has been enrolling patients at clinical sites across Northern and Central Europe.

Aquinox Pharmaceuticals Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 03:00 PM

Aquinox Pharmaceuticals Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 03:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: David J. Main, Co-Founder, Chairman, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQXP:US $8.89 USD -0.0001

AQXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQXP.
View Industry Companies
 

Industry Analysis

AQXP

Industry Average

Valuation AQXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUINOX PHARMACEUTICALS INC, please visit www.aqxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.